Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2013

Bioserv and Advantar Target a Comprehensive Value Chain

  • Bioserv signed a nonexclusive collaboration agreement with Advantar Laboratories to combine each firm’s capabilities for the creation of an improved value chain for client companies. Specifically, Bioserv will partner with Advantar Laboratories to offer its customers a portfolio of integrated service offerings.

    “The Bioserv-Advantar alliance [will provide] access to early formulation and analytical method development expertise, plus high-quality aseptic and non-aseptic manufacturing of liquids, powders, gels, and lyophilized drug products,” said Al Hansen, chairman and CEO of Bioserv. “The Bioserv-Advantar alliance will also provide its customers with labeling, kitting, storage, and shipment services. Our collaboration creates multiple synergies that will benefit customers in terms of quality, timeliness, and cost-effectiveness. It is truly a ‘win-win’ for both organizations.”

    Bioserv is engaged in pharmaceutical cGMP contract manufacturing, clinical packaging, and cold chain and distribution services, while Advantar brings analytical testing, biophysical characterization, drug product formulation, and litigation support services to the table.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »